Sort
48,018 grants matching “immunotherapy”
Recognition of Self and Mutated Self by Autoimmune and Tumor-Specific TCRs
$384,690Roy A Mariuzza · Univ Of Maryland, College Park · R01 · FY2012 · AI
Bacterial and Liposomal Antigen Processing
$384,689Clifford V Harding · Case Western Reserve University · R01 · FY2012 · AI
Bacterial and Liposomal Antigen Processing
$384,689Clifford V Harding · Case Western Reserve University · R01 · FY2011 · AI
Integration of neo-antigen vaccines and immune checkpoint therapy
$384,650Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2022 · CA
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$384,580Noah M Hahn · Johns Hopkins University · R01 · FY2021 · CA
Vaccine and radiation for the therapy of human cancers
$384,564James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Follicular Regulatory T-cells Promote Cancer
$384,562Jianmei Wu Leavenworth · University Of Alabama At Birmingham · R01 · FY2025 · CA
Novel Mechanisms Regulating Posttransplant Humoral Alloimmunity
$384,562Ginny L Bumgardner · Ohio State University · R01 · FY2012 · AI
Transcriptional and epigenetic mechanisms of immunotherapy resistance in melanoma
$384,559Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2019 · CA
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD
$384,518Dat Quoc Tran · University Of Texas Hlth Sci Ctr Houston · R01 · FY2016 · HL
Modulating pathogenic T cells in Type 1 diabetes
$384,483Kevan C Herold · Yale University · R01 · FY2022 · DK
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers
$384,482Zachary Conrad Hartman · Duke University · R01 · FY2024 · CA
Genetic dissection of Id3-mediated pathways in gamma/delta lineage development
$384,469Yuan Zhuang · Research Inst Of Fox Chase Can Ctr · P01 · FY2017 · AI
EOTAXIN AND NOVEL EOSINOPHIL RECEPTORS AND ASTHMA
$384,457Massachusetts General Hospital · R01 · FY2000 · AI
Longitudinal cohort of newly acquired HCV infection
$384,435Natl Centre/Hiv Epidemiology/Clncl Res · R01 · FY2004 · DA
SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses
$384,391Kirill A Afonin · University Of North Carolina Charlotte · R35 · FY2024 · GM
Studying the initiation, progression and therapy of lung cancer in mouse models
$384,375Martin McMahon · University Of Utah · R01 · FY2023 · CA
Development of mAb immunotherapy for genetically modified plague
$384,358James B Bliska · Columbia University Health Sciences · U54 · FY2009 · AI
Analyses of human T regulatory cells
$384,357Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$384,278Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2023 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$384,278Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2022 · CA
PD-1/PD-L1 signaling at the interface between immune and stem cell crosstalk
$384,250Melissa L Harris · University Of Alabama At Birmingham · R56 · FY2025 · AI
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity
$384,242Xiaoliu Zhang · University Of Houston · R01 · FY2025 · CA
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity
$384,242Xiaoliu Zhang · University Of Houston · R01 · FY2022 · CA
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages
$384,229James Louis Rubenstein · University Of California, San Francisco · R01 · FY2014 · CA